Xiaodong Wang Biography and Net Worth

Insider of BeOne Medicines

Xiaodong Wang, Ph.D. is a co-founder of BeiGene and has served as Chairman of our Scientific Advisory Board since 2011. Dr. Wang has been on the Board of Directors since February 2016.

Dr. Wang is the founding Director of the National Institute of Biological Sciences in Beijing, serving since 2003, and became its Director and Investigator in 2010. He previously served as a Howard Hughes Medical Institute Investigator (1997-2010) and was the George L. MacGregor Distinguished Chair Professor in Biomedical Sciences at the University of Texas Southwestern Medical Center in Dallas, Texas (2001-2010).

Dr. Wang received his Ph.D. in biochemistry from the University of Texas Southwestern Medical Center and B.S. in biology from Beijing Normal University. In 2004 Dr. Wang became a member of the U.S. National Academy of Sciences – one of the highest honors attainable by an American scientist – and has been a foreign associate of the Chinese Academy of Sciences since 2013.

What is Xiaodong Wang's net worth?: The estimated net worth of Xiaodong Wang is at least $1.41 billion as of March 4th, 2025. Wang owns 5,240,882 shares of BeOne Medicines stock worth more than $1,413,465,875 as of July 15th. This net worth approximation does not reflect any other investments that Wang may own. Learn More about Xiaodong Wang's net worth.
How do I contact Xiaodong Wang?: The corporate mailing address for Wang and other BeOne Medicines executives is C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN, E9, KY1-1108. BeOne Medicines can also be reached via phone at 13459494123 and via email at [email protected]. Learn More on Xiaodong Wang's contact information.
Has Xiaodong Wang been buying or selling shares of BeOne Medicines?: Xiaodong Wang has not been actively trading shares of BeOne Medicines during the past quarter. Most recently, Xiaodong Wang sold 2,007 shares of the business's stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $265.50, for a transaction totalling $532,858.50. Learn More on Xiaodong Wang's trading history.
Who are BeOne Medicines' active insiders?: BeOne Medicines' insider roster includes Chan Lee (SVP), John Oyler (CEO), Lai Wang (Global Head of R&D), Lai Wang (Insider), Xiaodong Wang (Insider), and Xiaobin Wu (COO). Learn More on BeOne Medicines' active insiders.
Are insiders buying or selling shares of BeOne Medicines?: In the last twelve months, insiders at the sold shares 31 times. They sold a total of 1,283,621 shares worth more than $329,355,099.37. The most recent insider tranaction occured on July, 9th when CEO John Oyler sold 27,802 shares worth more than $7,044,470.76. Insiders at BeOne Medicines own 6.6% of the company. Learn More about insider trades at BeOne Medicines.
Information on this page was last updated on 7/9/2025.

Xiaodong Wang Insider Trading History at BeOne Medicines

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/24/2025	Sell	2,007	$265.50	$532,858.50
6/10/2025	Sell	41,760	$262.82	$10,975,363.20
5/13/2025	Sell	41,760	$223.50	$9,333,360.00
4/14/2025	Sell	41,760	$242.66	$10,133,481.60
3/18/2025	Sell	41,760	$261.28	$10,911,052.80
3/4/2025	Sell	8,146	$254.58	$2,073,808.68	5,240,882

Xiaodong Wang Buying and Selling Activity at BeOne Medicines

BeOne Medicines Company Overview

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Today's Range

Now: $269.70

$263.84

$270.00

50 Day Range

MA: $247.15

$219.95

$276.53

2 Week Range

Now: $269.70

$146.87

$287.88

Volume

674,434 shs

Average Volume

290,157 shs

Market Capitalization

$29.56 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.28